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Historically, studies of brain metabolism have been
based on targeted analyses of a limited number of
metabolites. Here we present an untargeted mass
spectrometry-based metabolomic strategy that has
successfully uncovered differences in a broad array
of metabolites across anatomical regions of the
mouse brain. The NSG immunodeficient mouse
model was chosen because of its ability to undergo
humanization leading to numerous applications in
oncology and infectious disease research. Meta-
bolic phenotyping by hydrophilic interaction liquid
chromatography and nanostructure imaging mass
spectrometry revealed both water-soluble and lipid
metabolite patterns across brain regions. Neuro-
chemical differences in metabolic phenotypes were
mainly defined by various phospholipids and several
intriguing metabolites including carnosine, choles-
terol sulfate, lipoamino acids, uric acid, and sialic
acid, whose physiological roles in brain metabolism
are poorly understood. This study helps define
regional homeostasis for the normal mouse brain to
give context to the reaction to pathological events.
INTRODUCTION
Metabolomics entails the elucidation of the biochemical pro-
cesses engaged at the systems level (e.g., cell, tissue, or organ-
ismal) via the measurement of the end products of cell activity.
The subdiscipline of central nervous system (CNS) metabolo-
mics has recently emerged as a part of basic and applied clinical
investigations into degenerative, infectious, cancerous, and in-
flammatory disorders (Dumas and Davidovic, 2013; Mandal
et al., 2012; Nicholson et al., 2012). The role of metabolomics
in brain disease rests in measuring and deciphering the spec-
trum of small molecules that affect neurophysiologic (e.g., neu-
rotransmitters, signaling lipids, and osmolytes) and cell signaling
(e.g., regulators of cytokines and of oxidative stress, interme-
diary and energy currency metabolites) life processes (Piomelli
et al., 2007). The creation of a detailed map of the human neural
network (known as the connectome) (Sporns, 2011) and itsChemistry & Biology 21, 1575–158metabolic bridge will help to build a knowledge base to unravel
complex brain functions. For example, assessment of intraneural
and interneural communications and complex interactions
among brain regions and subregions will ultimately define how
metabolites mediate neural function. This is of vital importance
since brain metabolism goes beyond neurotransmission and
the variations in energy metabolism underlie normal homeosta-
sis and the complex pathobiology in a broad range of CNS
disorders (Cai et al., 2012; Davidovic et al., 2011; Dumas and
Davidovic, 2013; Holmes et al., 2006; Prabakaran et al., 2004)
Although the use of metabolomics for studies of neural func-
tion, in health and disease, is gaining critical attention, this field
still faces real challenges related, in part, to the intrinsic inacces-
sibility of the metabolome (Griffin and Salek, 2007; Rae, 2014).
While biofluid metabolite profiling of cerebrospinal fluid (CSF),
plasma, and urine have been applied, their limitations are well
recognized. One notable obstacle to the use of biofluids to reflect
nervous system pathobiology is the blood-brain barrier (BBB)
that serves to limit the passage ofmetabolites from theperiphery.
Thus, thedegree towhichbiofluids (specifically plasmaandurine)
mirror brain health or disease, in particular, is contested (Do-
mange et al., 2011; Griffin and Salek, 2007). Indeed, to unequiv-
ocally gain access to the brain metabolome, the tissue must be
considered. Human brain tissue, while being the most relevant
to study, is difficult to procure, especially in the case of control
samples. Such studies are further complicated by postmortem
delays thatmayaffectmetabolite degradation. Therefore, studies
in relevant animal models of human health and disease are
crucial. Animal models, including transgenic and humanized
mice, can mirror human disease events (Gorantla et al., 2012)
and enable the ‘‘true’’ metabolomics expressed in the phenotype
to assess complex neural processes (Domange et al., 2011).
Among the analytical techniques used in metabolomics, high
resolution proton NMR (1H-NMR) and liquid-chromatography-
mass spectrometry (LC/MS) are widely applied for biofluid
profiling, whereas high resolution magic angle spinning NMR
and magnetic resonance spectroscopy (MRS) are used to
analyze brain tissue (Blu¨ml et al., 2013; Domange et al., 2011).
Among molecular imaging assays, MRI and positron emission
tomography have enabled in vivo anatomical and functional
studies (Rae, 2014). The ex vivo imaging of brain tissue can
be performed by several mass spectrometry-based techniques
(Hanrieder et al., 2013): MALDI (Cerruti et al., 2012; Fournier
et al., 2011; Murphy et al., 2009), secondary ion mass spec-
trometry (Hanrieder et al., 2014; Sjo¨vall et al., 2004), and4, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1575
Figure 1. Global Metabolomic Approach for Regional Mapping of
Brain Tissue
This workflow integrates two complementary technologies, untargeted LC/MS
profiling using hydrophilic interaction chromatography (HILIC) coupled to elec-
trospray ionization (ESI) mass spectrometry and nanostructure imaging mass
spectrometry (NIMS). Following the heat fixation (FBMI), the left brain hemi-
sphere was dissected and each brain region was extracted separately for un-
targetedLC/MSprofiling (micespecimens=5).The intact rightbrainhemisphere
was imagedby laserdesorption-ionizationmassspectrometry tocreatemapsof
spatial distribution of metabolites of interest across the brain and within each
subregion.
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2012; Patti et al., 2010). These techniques are mainly used for
the analysis of functional brain peptides and lipids.
Amajority of brainmetabolism studies employ a targeted anal-
ysis of a small set of known, well defined metabolites (Bathena
et al., 2012; Ivanisevic et al., 2013; Yanes et al., 2011). For
example, 1H-NMR has been used to uncover specific highly
abundant metabolites (N-acetyl-aspartate, myo-inositol, gluta-
mate, glutamine, creatine, choline, and GABA). Such studies
have proven to be a key for the characterization of neurochemical
and metabolic profiles relevant to brain health (Davidovic et al.,
2011; Liu et al., 2013; Pears et al., 2005; Prabakaran et al.,
2004; Tka´c et al., 2004). Granting high reproducibility, the MR
technologies are restricted by their low sensitivity, which hinders
comprehensive pathologic assessments. Compared with NMR,
mass spectrometry has the advantage of being a highly sensitive
approach that can capture the variation of thousands of metabo-
lites, including those present at relatively low concentrations (as
low as picomolar) (Ivanisevic et al., 2013; Yanes et al., 2011). Sur-
prisingly, metabolic profiling using LC/MS, which is themost ver-
satile technique in metabolomics, has rarely been applied to
brain tissue (Graham et al., 2013; Inoue et al., 2013). While tar-
geted approaches are focused on analyses of a defined, limited
number of metabolites, untargeted assays profile thousands of
metabolite features without an a priori hypothesis (Patti et al.,
2012b, 2012c). Such holistic analyses can uncover unanticipated
roles of specific metabolites and the associated biochemical
pathways. To achieve this goal, we have performed global
metabolite profiling across anatomical regions of the brain, using
high-throughput, high-resolution mass spectrometry. The NOD/
SCID/IL2Rgc/ (NSG) mousewas chosen for its abilities to sup-
port humanization and its rapid evolving utilities in developing
novel therapeutic strategies for infectious and cancerous dis-
eases (McDermott et al., 2010; Rongvaux et al., 2014). Focused
beam microwave irradiation (FBMI) was applied to deliver a
high power pulse to induce instant euthanasia, simultaneously
halting brain enzyme activities (Epstein et al., 2013). Effective-
ness of FBMI was validated in each animal using noninvasive
postmortem 1H-MRS of brain tissue. A complex brain metabo-
lomewas successfully recovered by hydrophilic interaction liquid
chromatography-electrospray ionization-mass spectrometry
(HILIC-ESI-MS). The acquired signatures of each brain region
enabled the definition of differential metabolite patterns or me-
tabotypes. The diversity of metabolite patterns across the brain
and its relation to region-specific function was further investi-
gated through multigroup comparison by the analysis of most
discriminative metabolites. Nanostructure imaging mass spec-
trometry (NIMS) of brain tissue allowed for complementary and
subregional spatial distribution of specificmetabolites. The infor-
mation about region-specific metabolite enrichments reported
here provides a link between the anatomical and functional differ-
ences among brain regions.
RESULTS AND DISCUSSION
Global Metabolomics of Brain Anatomy Using LC/MS
and NIMS Profiling
Studies of brain metabolism at the regional level are surprisingly
scarce and when performed generally use targeted approaches1576 Chemistry & Biology 21, 1575–1584, November 20, 2014 ª2014to interrogate a small subset of metabolites whose physiological
roles are well described. The current untargeted LC/MS
approach, in concert with the power of matrix-free NIMS, has
been developed for simultaneous measurement of large
numbers of diverse metabolites with a broad range of functional
properties. Liquid chromatography coupled to mass spectrom-
etry is considered as the most comprehensive and versatile
technique of choice for global metabolite profiling efforts (Patti
et al., 2012c). To integrate LC/MS profiling and NIMS, one brain
hemisphere was dissected and each region was separately ex-
tracted for untargeted LC/MS analyses (mice specimens = 5),
while the other (intact) hemisphere was used for NIMS analyses
(Figure 1). The application of an amino-based column for LC/MS
profiling and the amino-based NIMS initiator used for imaging
has further facilitated this combined approach for the screening
of small polar central carbon metabolites. In this way NIMS has
enabled the acquisition of complementary information about
the local anatomical distribution of specific ions of interest.
The comprehensive, semiquantitative HILIC-ESI-MS profiling
was applied in negative ionization mode to maximizeElsevier Ltd All rights reserved
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metabolite profiles (metabotypes) were acquired for the frontal
cortex, dorsal cortex, ventral cortex, striatum, hippocampus,
thalamus-midbrain, brain stem, and cerebellum. The analytical
strategy of hydrophilic interaction enabled the detection of
15,835 lipid and water-soluble metabolite features across all
brain regions, including the highly abundant, well-characterized
brain metabolites (Fei et al., 2014) (e.g., glutamate, taurine, N-
acetylaspartate [NAA], N-Acetylaspartylglutamic acid [NAAG];
Figure S3 available online). Each of these metabolite features
corresponds to a detected ion with a unique mass-to-charge ra-
tio and a unique retention time (Patti et al., 2012a; Yanes et al.,
2011). It should be noted that metabolites can be defined by
several metabolite features matching isotope, adduct, and in-
source fragment peaks. In parallel to major classes of abundant
phospholipids (e.g., phosphatidylcholines [PC], phosphatidyl-
ethanolamines [PE], phosphatidylserines [PS], phosphatidylino-
sitols [PI], and phoshoglycerols [PG]) hydrophilic profiling of
brain regions permitted detection of central carbon metabolites,
nutrients, and metabolic byproducts of cellular metabolism.
These included nucleotides, amino, nonamino organic acids,
and specific neuropeptides (Figures S1–S3). Although LC/MS
has often been used for biofluid profiling to identify the metabo-
lite biomarkers of specific brain dysfunction, this highly sensitive
technique has rarely been applied to brain tissue profiling (Gra-
ham et al., 2013). It is likely that even when brain tissue is avail-
able, frombiopsies or in postmortem conditions, keymetabolites
may be lost due to rapid enzyme degradation. Rapid fixation is
critical to avoid hypoxia-related changes and metabolite degra-
dation in brain tissue. While flash freezing in liquid nitrogen, as
commonly used in metabolomics, may be suitable for peripheral
organs (e.g., lung, muscle, kidney, liver, and pancreas), even the
short delay between brain isolation and fixation results in meta-
bolic alterations under hypoxemic conditions (Griffin and Salek,
2007). Additionally, metabolites are degraded at different rates,
which further complicate analysis (de Graaf et al., 2009; Detour
et al., 2011). In particular, glucose and energy-linked phosphates
are prone to degradation within seconds of mammalian death
(Lowry et al., 1964). Key to detecting and measuring these me-
tabolites was the use of FBMI, which precludes rapid metabolite
degradation in the brain (Epstein et al., 2013; O’Callaghan and
Sriram, 2004). When FBMI is applied to live anesthetized mice
instant euthanasia ensues, quenching cellular metabolism
including enzyme activities (Epstein et al., 2013). The efficiency
of FBMI fixation was evaluated using 1H-MRS. Specifically,
NAA and lactic acid levels were measured and compared with
levels measured in living anesthetized mice. Samples with
reduced levels of NAA and increased lactic acid were discarded.
It has been demonstrated that NAA is synthesized in the mito-
chondria of neurons and thus hypoxia may reduce NAA by
reduction in mitochondrial metabolism (Bates et al., 1996). To
avoid further changes in metabolite levels and dissipation of
local concentration gradients of other metabolites, the brains
(n = 5) were dissected and frozen within 30min of FBMI. It should
also be noted that the results presented here are representative
of mice in a sleep state as metabolic pathways are differentially
regulated and specific areas of the brain may be less active dur-
ing anesthesia. To this point, FBMI could be adapted to quench
brain metabolism during an awake state and/or during a specificChemistry & Biology 21, 1575–158task (e.g., sensory stimulation) in order to avoid the potential
effects of anesthesia on brain metabolism.
Fixation methods, such as funnel freezing or the application of
microwaves on an intact live brain coupled to 1H-MRS validation,
as used in this report, ensure the efficient quenching of meta-
bolism (Detour et al., 2011). When metabolism quenching is per-
formed correctly, the advantage of brain tissue over biofluid
profiling is significant as limited passage of metabolites by
BBB, and differences between the brain parenchyma and CSF,
presentmajor pitfalls for the use of biomarkers frombiofluid anal-
ysis. The analysis of brain tissue samples provides unique infor-
mation about localized metabolic activity.
Metabolite Patterns across Anatomical Brain Regions
The knowledgebase for regional distribution of brain metabolites
is contradictory (Minati et al., 2010) and limited to a small set of
molecules that can be profiled in vivo by proton magnetic reso-
nance spectroscopy (Pouwels and Frahm, 1998). The results of
these studies, although not global in their scope, have already
demonstrated variation in metabolite concentrations across
different brain regions. In this report multigroup analysis of global
LC/MS profiles was used to characterize the diversity and varia-
tion of a broad range of metabolites across anatomical brain re-
gions. Multigroup comparison is an extension of the traditional
two-group experimental design (control versus disease) that per-
mits broad comparisons of three or more sample classes
(Gowda et al., 2014). Untargeted LC/MS profiling in hydrophilic
interaction mode followed by multigroup comparison enabled
the identification of a large number of differentially expressed
metabolite features across eight profiled brain regions. A total
of 561 significant differences (p % 0.01) were observed in the
lipid and water-soluble brain metabolome, as shown on the
cloud plot (Figure 2). For example, the variation pattern of glyc-
erophosphoserine (22:6/22:6) revealed significantly higher con-
tent in the brain stem and cerebellum in comparison with cortex
and other brain regions (Figure 2B). Among hydrophilic metabo-
lites, NAAG, a highly abundant neurotransmitter, was present in
significantly higher levels in thalamus-midbrain, brain stem, and
cerebellum compared with the cortex, striatum, and hippocam-
pus (Figure 2B). These results were in accordance with the con-
centrations determined by quantitative localized proton MRS,
which specified that NAAG increased caudally and exhibited
higher concentrations in white matter than in gray matter (Pou-
wels and Frahm, 1998). Multigroup analysis also confirmed
that NAA (in contrast to NAAG) was distributed homogeneously
throughout the brain (Figure S3).
Variation patterns of 60 significantly fluctuating metabolites
(p% 0.01, q% 0.001) were used to cluster the brain regions (Fig-
ure 3; Figures S1–S3). Hierarchical clustering analysis (HCA)
revealed two distinct groups. One comprised the midbrain, cer-
ebellum, and brain stem and the other comprised the cortex, hip-
pocampus and striatum. The samples within the first cluster
formed three separate subgroups matching specific brain re-
gions: cerebellum, brain stem (pons-medulla), and thalamus-
midbrain. The samples within the second major cluster were
sorted randomly into smaller subgroups, not relevant to specific
brain regions. Thalamus-midbrain, cerebellum, and brain stem
were characterized by specific, differential metabolite profiles
in comparison with the cortex, striatum, and hippocampus,4, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1577
Figure 2. Representation of Global Metabo-
lomic Data with a Focus on Significant Dif-
ferences in Metabolite Patterns across
Brain Regions
(A) Multigroup cloud plot showing differentially
expressed metabolite features (bubbles) across
different regions of brain (level of significance: p%
0.01, intensity > 20,000 ion counts). Metabolite
features are projected depending on their m/z ratio
and retention time. The color of the bubble in-
dicates the level of significance (p value), with
darker color (in red tones) representing lower p
values. A total ion chromatogram is shown in the
background.
(B) Variation patterns of two characteristic lipid
and water-soluble brain metabolites across eight
different regions of brain. Metabolites were iden-
tified on the basis of MS/MS data provided in
Figure S5 (NAAG) and in Table S2 (PS 22:6/22:6).
ANOVA was used to calculate the statistical sig-
nificance for n = 5 in each group. Box and whisker
plots display the full range of variation (whiskers:
median with minimum  maximum; boxes: inter-
quartile range).
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eral, the orthogonal partial least square discriminant analysis
(OPLS-DA) model, using all aligned metabolite features across
brain regions (>15,000), supported the HCA classification (Fig-
ure 4). Overlapping metabolite patterns in the forebrain that in-
cludes cortex, hippocampus, and striatum could support neural
connections and hence commonmetabolic activities (Cenquizca
and Swanson, 2007).
Predominant differences among defined regional clusters in
the brain were characterized by specific patterns of lipids and
their derivatives. In addition to different types of phospholipids
(PEs, PCs, PGs, PSs, and PIs), the cholesterol sulfate, two lipoa-
mino acids (N-docosanoyl taurine and N-palmitoyl serine), and
phosphoethanolamine were identified among the discriminatory
metabolites driving the brain region classification (Figure 3).
Cholesterol sulfate displayed a particular variation pattern, char-
acterized by significantly higher levels in the cerebellum as
compared with all other brain regions (Figure S1). N-docosanoyl
taurine and N-palmitoyl serine demonstrated a similar variation
profile with the highest content in thalamus-midbrain and brain
stem (Figure S2), while phosphoethanolamine displayed the
opposite pattern with the lowest levels in thalamus-midbrain,
brain stem, and cerebellum (Figure S1). Beyond specific lipid
metabolites, carnosine, and two carboxylic acids, sialic (N-ace-
tylneruraminic acid) and uric acid also contributed to the defini-
tion of differential metabolic phenotypes across brain (Figure S1).
The highest levels of both carnosine and uric acid were detected
in the frontal cortex. The sialic acid pattern showed significantly
lower levels in the hindbrain (cerebellum and brain stem).
Taking into consideration the variation patterns of identified
lipid and central carbon metabolites, the observed classification
of brain regions is likely influenced by a combination of several1578 Chemistry & Biology 21, 1575–1584, November 20, 2014 ª2014 Elsevier Ltd All rights redifferent factors, including the prevalent
neural cell types, white matter tracts
(visualized using NIMS imaging videinfra), neurotransmitter profile, and blood vasculature. The
gray-to-white matter ratio across specific regions may explain
the variation pattern of different lipid metabolites. For instance,
as shown by the heatmap (Figure 3), some phospholipids ex-
hibited pronounced regional variability with increasing or
decreasing levels depending on the caudally decreasing
gradient in gray matter. However, a number of specific glycero-
phosphoserines displayed significant contrasting levels be-
tween frontal and caudal brain regions (Figures 2 and 3), where
they may serve as a metabolic reservoir for free serine and regu-
late serine-dependent neurotransmission (Kopp et al., 2010).
Another intriguing finding related to lipid metabolite patterns
was a significant high level of cholesterol sulfate in cerebellum
when compared with other brain regions. Sulfonation of choles-
terol is ubiquitous in cell membranes throughout the body, acti-
vating cholesterol for cell adhesion and osmoprotection (Strott
and Higashi, 2003). Cholesterol sulfate may regulate the synthe-
sis of cholesterol, which is vital for nerve signal transduction and
synaptogenesis, but in excess leads to neurodegeneration
(Vance, 2012). However, the specific role of cholesterol sulfate
associated to cerebellum function remains to be elucidated.
Furthermore, the evaluation of metabolite patterns across
brain regions uncovered high levels of free radical scavengers
in the frontal cortex. This includes, notably, uric acid and carno-
sine, which are known to be antioxidants and neuroprotective
agents (Fang et al., 2013; Bae et al., 2013). This regional spec-
ificity may be linked to surveillance responses, which serve to
reduce oxidative stress and protect against oxidative damage.
Uric acid was found at lower levels in patients with cognitive
impairment (e.g., Alzheimer’s disease, Parkinson’s disease,
vascular-linked dementia) when compared with aged individ-
uals who enjoy normal mental, motor, and behavioral functionsserved
Figure 3. Heatmap and Associated Dendograms Representing the Hierarchically Clustered Samples Based on the Similarity of Metabolite
Patterns
Discriminating metabolites (ANOVA p% 0.01, q% 0.001, Intensity > 20,000) are shown on the right side. Isotopes, adducts, in-source fragments, and multiply
charged features were filtered out. MS/MS data for identified metabolites are provided in Figures S4 and S5. MS/MS patterns for putative identifications of
phospholipids are given in Tables S2 and S3. Variation patterns of identified metabolites (with the exception of phospholipids) are presented by box and whisker
plots in Figures S1 and S2.
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carnosine is a potent antioxidant that scavenges reactive oxy-
gen species and unsaturated aldehydes leading to reduced
oxidative, nitrosative, and glycemic stress (Bellia et al., 2011).
Like uric acid, carnosine levels are reduced in Alzheimer’s dis-
ease, suggesting that carnosine deficiency affects cognitive
function (Fonteh et al., 2007). Frontal cortical areas have a com-Chemistry & Biology 21, 1575–158plex role in cognitive function and the high content of uric acid
and carnosine as homeostatic metabolites may be associated
with the need for internal control by the brain in preventing
oxidative damage.
Global metabolite profiling provided insights into the unantic-
ipated roles of characteristic metabolites associated with
intermediary and energy metabolism as well as membrane4, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1579
Figure 4. Supervised Pattern Recognition OPLS-DA Model for
Metabolomic Profiles of Brain Regions
OPLS scores plot of HILIC-ESI-MS profiles (aligned by XCMS) shows
discrimination among specific regions on the first and second component. The
model brings out the specific variation of the metabolite composition ac-
cording to the brain region (five biological replicates per region). Good sepa-
ration was achieved for three different regions: midbrain, brain stem, and
cerebellum. All aligned metabolite features (15,835) were used to create the
model, and a total of five orthogonal components were calculated for cross-
validation (R2Y(cum) = 0.68, Q2Y(cum) = 0.35).
Figure 5. Laser Desorption-Ionization MS Images or Maps of Ions of
Interest
Extracted maps from the lowmass part of total ion spectra (<500 Da) show the
spatial distribution of docosahexaenoic acid (DHA), glutamine, carnosine, and
docosanoyl taurine. Extracted maps from the higher mass part of total ion
spectra (>800 Da) show the spatial distribution of sulfatide and phosphati-
dylserine. Images were acquired from a 2 mm thin brain section that was
mounted on etched silicon chip, coated with PFUA initiator, prior to imaging in
negative ionization mode. Ions of interest were identified using the MS/MS
data acquired by LC/MS profiling (Figures S3 and S4; Table S3).
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connotation of neurochemical changes can be further explored
through biochemical assays and/or isotope-labeled tracking
experiments to elucidate the active metabolic pathways and
functionally better characterize brain regions (Vaishnavi et al.,
2010).
NIMS imaging was employed to provide subregional chemical
information to aid in the interpretation of global metabolite
profiling results. Matrix-free NIMS strategy was introduced
based on using pulsed-laser desorption and ionization with a sil-
icon nanostructured surface (Wei et al., 1999). Matrix-free appli-
cation represents themain advantage over MALDI where the use
of organic matrices can present interference when attempting to
detect small molecules (less than 500 Da) (Greving et al., 2011).
Moreover, laser desorption from the nanostructure surfaces re-
sults in efficient energy transfer, low background chemical noise,
and the nondestructive release of analyte ions into the gas
phase. Detecting these ions as a function of position yields a
spatially resolved chemical map of the surface. Nanostructure
imaging mass spectrometry of sagittal brain sections provided
insights into the spatial distribution of specific metabolites within
the profiled anatomical regions. The application of an amino-
based initiator to the surface of etched silicon chips facilitated
the desorption and ionization and imaging of broader range of
negatively charged metabolites (Figure 5). The extracted maps
of two specific ions matching docosahexaenoic acid (DHA)
and C24:1 sulfatide reflect gray and white matter patterns (Fig-
ure 5). DHA is abundant in the gray matter as a developmentally
vital component of neuronal membranes and synapses (Salem
et al., 2001). Moreover, DHA metabolism is an active process
of neuronal membrane functions in the gray matter as seen
with radiolabeled DHA uptake and retention rates measured in
human brain imaging studies (Umhau et al., 2009). Interestingly,
even though these metabolites are differentially distributed
throughout the brain they do not contribute to the regional clus-1580 Chemistry & Biology 21, 1575–1584, November 20, 2014 ª2014tering observed using LC/MS analysis because of an averaging
effect that is implicit when homogenizing a heterogeneous brain
region. The high lateral resolution is additive to the global metab-
olomics approach in that it provides subregional context,
showing the heterogeneity of each region, which is obscured
by the gross analysis of the whole.
SIGNIFICANCE
The metabolome is an essential component of brain func-
tion. However, its complete characterization poses substan-
tive challenges and as such is limited to a targeted set of
highly abundant small molecules investigated through mag-
netic resonance technology. In order to gain comprehensive
insight into the metabolic processes that mediate neural
function, we have developed an untargetedmass spectrom-
etry-based approach that permits relative quantification of a
broad range of lipid and water-soluble metabolites. The
approach combines HILIC/MS and NIMS technology to
assess divergent anatomical brain regions including the cor-
tex, striatum, hippocampus, thalamus-midbrain, stem, and
cerebellum. Focused microwave beam fixation was per-
formed to limit profile changes related to postmortem delay.Elsevier Ltd All rights reserved
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significant differentially expressed metabolites that were
used to hierarchically cluster brain regions. Various phos-
pholipids and several intriguing metabolites, including
carnosine, uric and sialic acid, cholesterol sulfate, and
lipoamino acids were identified among the most discrimi-
nating metabolites. Significant differences in metabolite
patterns were observed between the cluster comprising
the caudal regions (midbrain, stem, and cerebellum) and
the cluster comprising the forebrain regions (cortex, stria-
tum, and hippocampus). The former were each highlighted
by specific metabolomic signatures, while the latter dis-
played similar metabolite patterns. Greater similarity in
metabolite patterns could represent a higher level of interac-
tion between brain regions. Brain mapping of the metabo-
lites by NIMS provided complementary information about
the metabolite distribution within the brain regions. Overall,
the untargeted profiling of brain tissue combined with nano-
structure imaging mass spectrometry can encompass a
broad range of interacting metabolites with varying chemi-
cal and physical properties and thus provide new insights
into the complexities of neural function. Additionally, the un-
derstanding of regional metabolic differences in the normal
brain is essential for understanding the altered pathways in
pathological states.
EXPERIMENTAL PROCEDURES
Tissue Preparation
NOD/SCID/IL2Rgc/ (NSG) mouse model is described in the Supplemental
Information. Mice were anesthetized with 1%–2% isoflurane in oxygen then
aligned in a water-jacketed holder for microwave irradiation in a Muromachi
Microwave Fixation System (10 kW model). Irradiation time was 800 ms at
4.9 kW (Epstein et al., 2013). Single voxel localized spectra were acquired
postmortem at the midbrain to ensure metabolite level stabilization using point
resolved spectroscopy. Spectra were acquired with a repetition time of 4 s,
echo time of 50ms, and 128 averages, using birdcage coil transmit and receive
on a 7 Tesla/16 cmBruker Pharmascan (Karlsure, Germany)MRI/MRS system.
Single-scan, localized, unsuppressed water signals were acquired as a refer-
ence for metabolite normalization. Brains with abnormal NAA or lactate con-
centrations were eliminated from further analysis. Five specimens were
selected for further brain dissection and analysis. All specimens were from
the same genetic strain, males, and of similar ages. The animal studies per-
formed, in support of this research, were approved by the University of Ne-
braska Medical Center Institutional Animal Care and Use Committee and by
established values of the NIH for the ethical care and use of animals.
After spectroscopic validation of FBMI, brains were isolated and initially split
into hemispheres, with the left hemisphere reserved for cryosectioning and the
right hemisphere dissected into subregions. Subregional dissection followed
anatomical boundaries to separate hemi-brains into cerebellum, brain stem
(pons and medulla), cerebral cortex, hippocampus, striatum, and midbrain
(midbrain and thalamus). Cortex was further divided into frontal, dorsal (so-
matosensory through visual areas) and ventral (piriform through perirhinal
areas) sections. Following dissection, all tissues were flash frozen in liquid ni-
trogen and stored at 80C.
Metabolome Extraction
Brain tissue subregions were extracted using a MeOH:H2O (4:1, v/v) solvent
mixture. An adjusted volume of 1 ml of cold solvent was added per 10 mg
tissue, probe sonicated for 5 s, and incubated in liquid nitrogen for 1 min.
The samples were then allowed to thaw at room temperature and then probe
sonicated for another 5 s. To precipitate proteins, the samples were incubated
for 1 hr at20C, followed by 15min centrifugation at 13,000 rpm and 4C. The
resulting supernatant was removed and evaporated to dryness in a vacuumChemistry & Biology 21, 1575–158concentrator. The pellet was reconstituted in water and protein concentrations
were measured using Pierce BCA Protein Assay Kit (Thermo Scientific) as a
reference for metabolite reconstitution. The dry extracts were then reconsti-
tuted in ACN:H2O (1:1, v/v) normalized by the sample’s protein level, sonicated
for 10 min, and centrifuged 15 min at 13,000 rpm and 4C to remove insoluble
debris. The supernatants were transferred to high-performance liquid chroma-
tography vials and stored at 80C prior to LC/MS analysis.
HILIC/MS Analysis
Tissue extracts (8 brain regions 3 5 biological replicates) were analyzed on a
6550 iFunnel QTOF mass spectrometer (Agilent Technologies) interfaced with
HPLC 1200 system (Agilent Technologies). Samples were analyzed using a
Luna Aminopropyl, 3 mm, 150 3 1.0 mm I.D. HILIC column (Phenomenex).
The mobile phase was composed of A = 20 mM ammonium acetate and
40 mM ammonium hydroxide in 95% water and B = 95% acetonitrile (Ivani-
sevic et al., 2013). The linear gradient elution from 100% B (0–5 min) to
100% A (50–55 min) was applied (A = 95% H2O, B = 95% ACN, with appro-
priate additives). A 10 min postrun was applied for HILIC to ensure the column
reequilibration and maintain the reproducibility. The flow rate was 50 ml/min,
and the sample injection volume was 5 ml. ESI source conditions were set as
follows: dry gas temperature 200C and flow 11 l/min, fragmentor 380 V,
sheath gas temperature 300C and flow 9 l/min, nozzle voltage 500 V, and
capillary voltage2,500 V in ESI negativemode. The instrument was set to ac-
quire over the m/z range 50–1,000, with the MS acquisition rate of 2 spectra/s.
For the MS/MS of selected precursors, the default isolation width was set as
narrow (1.3m/z), with aMS acquisition rate at 2 spectra/s andMS/MS acqui-
sition at 3 spectra/s. MS/MS data were acquired at the collision energy of 20 V
and of 40 V.
NIMS
Information about preparation of NIMS surfaces (chips) is provided in the
Supplemental Information. Brain hemispheres were frozen in optimum cutting
temperature medium (OCT; Sakura Finetek) for cryo-sectioning. Frozen OCT-
embedded brain hemispheres were sliced along the sagittal plane into 2 mm
sections with a cryostat (Leica Microsystems) and placed on the NIMS chip
and immediately dried in a desiccated, room-temperature vacuum chamber.
Adjacent brain sections were collected and placed on glass tissue fixation
slides for immunofluorescence microscopy and hematoxylin and eosin stain-
ing. Thaw-mounted tissue sliceswere directly imaged using an ABSCIEX TOF/
TOF 5800 mass spectrometer (Applied Biosystems), equipped with a Nd:YAG
laser at 355 nm, without any sample preparation. Data were acquired at 50 mm
spatial resolution in negative ionization mode across the entire brain tissue.
Typically, 200 laser shots were collected per spectrum. Propafenone and bra-
dykinin fragments 2–9 were used to calibrate the instrument in the low-mass
range. Images were acquired using MS Imaging Tool software with a typical
resolution of 50 3 50 mm2. Data analysis and image reconstruction were per-
formed using BioMap software. Metabolite identifications were deduced from
mass value (within 50 ppm accuracy), METLIN matches, and MS/MS data
obtained by LC/MS/MS analysis.
Data Analysis
Raw LC/MS data were converted to mzXML files using ProteoWizard MS
Convert version 3.0.4146 (Chambers et al., 2012). The mzXML files were up-
loaded to XCMS Online web platform for data processing (https://
xcmsonline.scripps.edu) (Nikolskiy, et al., 2013; Patti et al., 2012a; Smith
et al., 2006; Tautenhahn et al., 2012) including peak detection, retention time
correction, profile alignment, and isotope annotation. Data were processed
as a multigroup design experiment, and the parameter settings were as fol-
lows: centWave for feature detection (Dm/z = 15 ppm, minimum peak width =
10 s, and maximum peak width = 120 s); obiwarp settings for retention time
correction (profStep = 1); and parameters for chromatogram alignment,
including mzwid = 0.015, minfrac = 0.5, and bw = 5. The relative quantification
of metabolite features was based on extracted ion chromatogram (EIC) areas.
One-way ANOVA and post hoc Tukey test was used to test the variation
pattern of metabolite features across different brain regions (Table S1). The re-
sults output, including EICs, and multigroup cloud plot were exported directly
from XCMS Online. Metabolite identification was based on accurate mass
(within 10 ppm) and MS/MS data. MS/MS data validated via matching against4, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1581
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Otherwise, the MS/MS fragmentation patterns are provided in Tables S2
and S3.
A heatmap was produced using R version 3.01 and the gplots library. A se-
lection of features whose expression varied significantly across different brain
regions (p < 0.01, q < 0.001, Intensity > 20,000 ion counts) were used to create
the heatmap. After filtering out the isotopes, adducts, multiple charged spe-
cies, and in-source fragments, only the corresponding deprotonatedmonoiso-
topic features were used for visualization. A z-transformation was performed
on all features to scale the data. Hierarchical clustering analysis (HCA) of
metabolite patterns was performed using the Euclidean distance matrix and
the complete linkage method.
The orthogonal projection to a latent structure-discriminant analysis (O2-
PLS-DA) model wasmade using SIMCA P+ 12.0 (Umetrics). All alignedmetab-
olite features were used for the analysis. The predictive variance, Q2, was
computed by testing on one-seventh of the data. Data were scaled using uni-
variate scaling because this showed the best predictive model. Themodel was
autofitted to find the optimal number of components.ACCESSION NUMBERS
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